Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 13, 770 - 771 (2007)
Published online: 29 June 2007 | doi:10.1038/nm0707-770
Second chance
Erika Check1
- Erika Check covers biomedical research for Nature from San Francisco.
Abstract
A California company is reviving a once abandoned treatment for Parkinson's disease. Erika Check assesses its odds of success.
Three years ago, Parkinson's disease research seemed on the verge of a breakthrough.California-based Amgen was delivering a protein directly into the brains of 34 people with the disease.
To read this story in full you will need to login or make a payment (see right).
